NFKB1 and colonic neoplasm: Pharmacologic inhibition of PI3K either with a reversible inhibitor LY or an irreversible inhibitor wortmanin significantly reduced DNA binding activity of NFkB in activin treated FET colon cancer cells (Figure 3C and 3D).